Baillie Gifford & Co Portfolio holdings
Baillie Gifford & Co., founded in 1908 by Lt Col Augustus Baillie and Carlyle Gifford and headquartered in Edinburgh, Scotland, is an independent, partnership-owned investment management firm renowned for its long-term, growth-oriented approach, managing over £230 billion ($290 billion USD) in assets as of late 2024. Focusing primarily on global equities, the firm serves institutional clients like pension funds and retail investors through mutual funds and investment trusts, such as the Scottish Mortgage Investment Trust, emphasizing fundamental research into innovative, high-growth companies—often holding stakes in firms like Tesla and Amazon for decades. With around 2,000 employees across offices in London, New York, Hong Kong, and beyond, Baillie Gifford operates without external ownership pressures, allowing its 58 partners to prioritize patience and conviction over short-term market trends. Known for its low-profile culture and ESG integration, the firm has earned a reputation as a thoughtful, contrarian investor in a world of rapid-fire trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABMD
Abiomed Inc
ABMD
|
+$302M |
| 2 |
Trade Desk
TTD
|
+$265M |
| 3 |
Illumina
ILMN
|
+$260M |
| 4 |
JMIA
Jumia Technologies
JMIA
|
+$260M |
| 5 |
AXON
Axon Enterprise
AXON
|
+$252M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verisk Analytics
VRSK
|
+$493M |
| 2 |
Baidu
BIDU
|
+$378M |
| 3 |
FRC
First Republic Bank
FRC
|
+$333M |
| 4 |
ICICI Bank
IBN
|
+$215M |
| 5 |
Stellantis
STLA
|
+$207M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 32.32% |
| 2 | Healthcare | 17.27% |
| 3 | Communication Services | 16.52% |
| 4 | Financials | 10.83% |
| 5 | Technology | 10.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
176
Infosys
INFY
$49.6B
| $14M | 0.01% |
1,304,732
+68,860
| +6% | +$729K |
|
177
Exelon
EXC
$47B
| $13.5M | 0.01% |
396,247
-371,707
| -48% | -$13.1M |
|
178
Adicet Bio
ACET
$85.2M
| $13M | 0.01% |
11,352
| – | – |
|
|
ORTX
179
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
| $12.9M | 0.01% |
92,500
| – | – |
|
180
Ecolab
ECL
$78.6B
| $12.7M | 0.01% |
64,382
+11,453
| +22% | +$2.13M |
|
|
ONC
181
BeOne Medicines Ltd
ONC
$32.6B
| $12.2M | 0.01% |
98,524
+2,950
| +3% | +$374K |
|
|
182
Verisk Analytics
VRSK
$25.1B
| $11.6M | 0.01% |
79,376
-3,496,189
| -98% | -$493M |
|
|
MRC
183
DELISTED
MRC Global
MRC
| $11.1M | 0.01% |
650,000
| – | – |
|
184
Veeco
VECO
$3.11B
| $10.5M | 0.01% |
859,481
-775,312
| -47% | -$9.39M |
|
185
CEVA Inc
CEVA
$910M
| $10.1M | 0.01% |
415,727
-2,039
| -0.5% | -$50.1K |
|
186
BlackRock Floating Rate Income Trust
BGT
$323M
| $9.96M | 0.01% |
802,170
| – | – |
|
|
VAR
187
DELISTED
Varian Medical Systems, Inc.
VAR
| $9.86M | 0.01% |
72,439
-36,465
| -33% | -$4.87M |
|
|
FTCH
188
DELISTED
Farfetch Limited Class A Ordinary Shares
FTCH
| $9.62M | 0.01% |
+462,330
| New | +$10.7M |
|
189
Sherwin-Williams
SHW
$86B
| $8.97M | 0.01% |
58,752
| – | – |
|
|
LN
190
DELISTED
LINE Corporation
LN
| $8.7M | 0.01% |
309,160
+1,563
| +0.5% | +$49.2K |
|
|
NCNA
191
NuCana
NCNA
$5.62M
| $8.59M | 0.01% |
165
| – | – |
|
192
Evolent Health
EVH
$353M
| $8.53M | 0.01% |
1,072,417
-967
| -0.1% | -$11.4K |
|
193
British American Tobacco
BTI
$131B
| $7.32M | 0.01% |
209,808
+2,824
| +1% | +$107K |
|
|
KDNY
194
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
| $6.27M | 0.01% |
814,145
+47,860
| +6% | +$729K |
|
|
PHD
195
DELISTED
Pioneer Floating Rate Fund
PHD
| $5.89M | 0.01% |
550,936
| – | – |
|
|
SINA
196
DELISTED
Sina Corp
SINA
| $5.67M | 0.01% |
131,550
| – | – |
|
|
KLDO
197
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
| $5.1M | 0.01% |
440,000
| – | – |
|
198
HUTCHMED
HCM
$2.01B
| $4.79M | 0.01% |
217,911
-2,985
| -1% | -$85.2K |
|
199
Rio Tinto
RIO
$156B
| $4.4M | ﹤0.01% |
70,626
| – | – |
|
200
SLB Ltd
SLB
$73.2B
| $4.39M | ﹤0.01% |
110,529
| – | – |
|
Similar funds
Baillie Gifford & Co's Q2 2019 Portfolio in Review
As of Q2 2019, Baillie Gifford & Co held 233 positions worth $94.3B, up 3.1% from $91.4B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Baillie Gifford & Co's Q2 2019 filing shows 6 new, 102 increased, 80 reduced and 7 closed positions. Its largest new stake was Jumia Technologies: 9,002,358 shares worth $238M. The largest sale was Verisk Analytics, an estimated $493M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 32% of assets, down from 34% a quarter earlier, followed by Healthcare and Communication Services.
- Baillie Gifford & Co's largest Q2 2019 buy was Jumia Technologies: 9,002,358 shares worth $238M.
- Baillie Gifford & Co added most to Abiomed Inc in Q2 2019, an estimated $302M increase.
- Baillie Gifford & Co's biggest Q2 2019 reduction was Verisk Analytics, cutting an estimated $493M.
- Baillie Gifford & Co fully exited Vertex Pharmaceuticals in Q2 2019, selling an estimated $78.2M.
- Baillie Gifford & Co's ten largest holdings make up 45% of its $94.3B portfolio in Q2 2019.
- Baillie Gifford & Co opened 6 new positions and closed 7 in Q2 2019.
- Baillie Gifford & Co's portfolio value rose 3.1% quarter-over-quarter to $94.3B.
Based on Baillie Gifford & Co's 13F filing for Q2 2019, filed 8 Aug 2019.